BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

762 related articles for article (PubMed ID: 30274685)

  • 1. MiR-137 suppresses migration and invasion by targeting EZH2-STAT3 signaling in human hepatocellular carcinoma.
    Huang B; Huang M; Li Q
    Pathol Res Pract; 2018 Dec; 214(12):1980-1986. PubMed ID: 30274685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential roles of EZH2, Bmi-1 and miR-203 in cell proliferation and invasion in hepatocellular carcinoma cell line Hep3B.
    Yang F; Lv LZ; Cai QC; Jiang Y
    World J Gastroenterol; 2015 Dec; 21(47):13268-76. PubMed ID: 26715809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EZH2 promotes hepatocellular carcinoma progression through modulating miR-22/galectin-9 axis.
    Chen S; Pu J; Bai J; Yin Y; Wu K; Wang J; Shuai X; Gao J; Tao K; Wang G; Li H
    J Exp Clin Cancer Res; 2018 Jan; 37(1):3. PubMed ID: 29316949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HANR promotes hepatocellular carcinoma progression via miR-214/EZH2/TGF-β axis.
    Shi Y; Yang X; Xue X; Sun D; Cai P; Song Q; Zhang B; Qin L
    Biochem Biophys Res Commun; 2018 Nov; 506(1):189-193. PubMed ID: 30342849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long noncoding RNA metastasis-associated lung adenocarcinoma transcript 1 cooperates with enhancer of zeste homolog 2 to promote hepatocellular carcinoma development by modulating the microRNA-22/Snail family transcriptional repressor 1 axis.
    Chen S; Wang G; Tao K; Cai K; Wu K; Ye L; Bai J; Yin Y; Wang J; Shuai X; Gao J; Pu J; Li H
    Cancer Sci; 2020 May; 111(5):1582-1595. PubMed ID: 32129914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA-26a suppresses epithelial-mesenchymal transition in human hepatocellular carcinoma by repressing enhancer of zeste homolog 2.
    Ma DN; Chai ZT; Zhu XD; Zhang N; Zhan DH; Ye BG; Wang CH; Qin CD; Zhao YM; Zhu WP; Cao MQ; Gao DM; Sun HC; Tang ZY
    J Hematol Oncol; 2016 Jan; 9():1. PubMed ID: 26733151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miR-98 inhibits hepatocellular carcinoma cell proliferation via targeting EZH2 and suppressing Wnt/β-catenin signaling pathway.
    Zhang JJ; Chen JT; Hua L; Yao KH; Wang CY
    Biomed Pharmacother; 2017 Jan; 85():472-478. PubMed ID: 27890434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity.
    Xu L; Beckebaum S; Iacob S; Wu G; Kaiser GM; Radtke A; Liu C; Kabar I; Schmidt HH; Zhang X; Lu M; Cicinnati VR
    J Hepatol; 2014 Mar; 60(3):590-8. PubMed ID: 24211739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo and in vitro effects of microRNA-221 on hepatocellular carcinoma development and progression through the JAK-STAT3 signaling pathway by targeting SOCS3.
    Huang S; Zhou D; Li YX; Ming ZY; Li KZ; Wu GB; Chen C; Zhao YN
    J Cell Physiol; 2019 Apr; 234(4):3500-3514. PubMed ID: 30370582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR-451 acts as a suppressor of angiogenesis in hepatocellular carcinoma by targeting the IL-6R-STAT3 pathway.
    Liu X; Zhang A; Xiang J; Lv Y; Zhang X
    Oncol Rep; 2016 Sep; 36(3):1385-92. PubMed ID: 27461244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA let-7c-5p Alleviates in Hepatocellular Carcinoma by Targeting Enhancer of Zeste Homolog 2: A Study Intersecting Bioinformatic Analysis and Validated Experiments.
    Lin T; Guo X; Du Q; Liu W; Zhong X; Wang S; Cao L
    Crit Rev Immunol; 2024; 44(4):23-39. PubMed ID: 38505919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. miR-345 inhibits tumor metastasis and EMT by targeting IRF1-mediated mTOR/STAT3/AKT pathway in hepatocellular carcinoma.
    Yu M; Xue H; Wang Y; Shen Q; Jiang Q; Zhang X; Li K; Jia M; Jia J; Xu J; Tian Y
    Int J Oncol; 2017 Mar; 50(3):975-983. PubMed ID: 28098858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LncRNA LEF1-AS1 silencing diminishes EZH2 expression to delay hepatocellular carcinoma development by impairing CEBPB-interaction with CDCA7.
    Gao J; Dai C; Yu X; Yin XB; Zhou F
    Cell Cycle; 2020 Apr; 19(8):870-883. PubMed ID: 32178558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long noncoding RNA GIHCG promotes hepatocellular carcinoma progression through epigenetically regulating miR-200b/a/429.
    Sui CJ; Zhou YM; Shen WF; Dai BH; Lu JJ; Zhang MF; Yang JM
    J Mol Med (Berl); 2016 Nov; 94(11):1281-1296. PubMed ID: 27380494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MiR-214 targets β-catenin pathway to suppress invasion, stem-like traits and recurrence of human hepatocellular carcinoma.
    Xia H; Ooi LL; Hui KM
    PLoS One; 2012; 7(9):e44206. PubMed ID: 22962603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circ_0072088 promotes progression of hepatocellular carcinoma by activating JAK2/STAT3 signaling pathway via miR-375.
    Li L; Xiao C; He K; Xiang G
    IUBMB Life; 2021 Sep; 73(9):1153-1165. PubMed ID: 34148288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EZH2-H3K27me3-mediated silencing of mir-139-5p inhibits cellular senescence in hepatocellular carcinoma by activating TOP2A.
    Wang K; Jiang X; Jiang Y; Liu J; Du Y; Zhang Z; Li Y; Zhao X; Li J; Zhang R
    J Exp Clin Cancer Res; 2023 Nov; 42(1):320. PubMed ID: 38008711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. P53 suppresses the progression of hepatocellular carcinoma via miR-15a by decreasing OGT expression and EZH2 stabilization.
    You Z; Peng D; Cao Y; Zhu Y; Yin J; Zhang G; Peng X
    J Cell Mol Med; 2021 Oct; 25(19):9168-9182. PubMed ID: 34510715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MiR-200c-5p suppresses proliferation and metastasis of human hepatocellular carcinoma (HCC) via suppressing MAD2L1.
    Li Y; Bai W; Zhang J
    Biomed Pharmacother; 2017 Aug; 92():1038-1044. PubMed ID: 28609841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA-486-5p, which is downregulated in hepatocellular carcinoma, suppresses tumor growth by targeting PIK3R1.
    Huang XP; Hou J; Shen XY; Huang CY; Zhang XH; Xie YA; Luo XL
    FEBS J; 2015 Feb; 282(3):579-94. PubMed ID: 25475121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.